The concentrations of free Gal-Hyl in serum and urine in the four groups are shown in Fig.
RESPONSE OF SERUM FREE Gal-Hyl DURING TREATMENT OF PAGET DISEASE OF BONE
Free Gal-Hyl in both serum and urine decreased significantly in response to 6 months of etidronate therapy in patients with Paget disease (Fig.
The fractional excretion of free Gal-Hyl was calculated from urinary and serum Gal-Hyl and Cr in 21 girls, ages 10-12 years, using the equation:
The mean fractional excretion of free Gal-Hyl was 0.
13) for the measurement of Gal-Hyl in urine is not suitable for measurement of the concentration of Gal-Hyl in serum because of the much lower serum concentration and protein interference.
The concentration of free Gal-Hyl in both serum and urine discriminated between premenopausal women, postmenopausal women, pubertal girls, and patients with untreated Paget disease, as would be expected.
There are several potential problems associated with the use of Gal-Hyl as an indicator of bone resorption.
It is also possible that Gal-Hyl could be absorbed from the diet.
Serum Gal-Hyl was increased in patients with Paget disease of bone, and decreased rapidly in response to bisphosphonate therapy.
In conclusion, measurement of free Gal-Hyl in serum by HPLC is possible.
Factors affecting the assay of urinary Gal-Hyl as marker of bone resorption [Abstract].